Mechanisms involved in the side effects of glucocorticoids

Pharmacology and Therapeutics

Volumn 96, Issue 1, 2002, Pages 23-43

  Schäcke, Heike ^a   Döcke, Wolf Dietrich ^a   Asadullah, Khusru ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Adverse effects; Immunosuppression; Immunotherapy; Pharmacology

Indexed keywords

BUDESONIDE; CLOBETASOL PROPIONATE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; METHYLPREDNISOLONE ACEPONATE;

ADRENAL INSUFFICIENCY; ARTICLE; CANDIDIASIS; CARDIOVASCULAR SYSTEM; CATARACT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; GLAUCOMA; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMMUNE SYSTEM; MOLECULAR BIOLOGY; MUSCLE ATROPHY; MYOPATHY; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PREDICTION; PRIORITY JOURNAL; SKIN ATROPHY; WOUND HEALING;

EID: 0036810356     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00297-8     Document Type: Review

References (223)

1. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D.L., Lentle B., Olszynski W., Ste-Marie L.G., Tenenhouse A., Chines A.A. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 337:1997;382-387.
2. Akkoca O., Mungan D., Karabiyikoglu G., Misirligil Z. Inhaled and systemic corticosteroid therapies: do they contribute to inspiratory muscle weakness in asthma? Respiration. 66:1999;332-337.
3. Allen D.B. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective. Acta Paediatr. 87:1998;123-129.
4. Allen D.B., Mullen M.L., Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 93:1994;967-976.
5. Andrews R.C., Walker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci. 96:1999;513-523.
6. Armaly M.F. Effects of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 70:1963;98-103.
7. Asher C., Wald H., Rossier B.C., Garty H. Aldosterone-induced increase in the abundance of Na+ channel subunits. Am J Physiol. 271:1996;C605-C611.
8. Autio P., Karjalainen J., Risteli L., Risteli J., Kiistala U., Oikarinen A. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Resp Crit Care Med. 153:1996;1172-1175.
9. Avioli L.V. Glucocorticoid effects on statural growth. Br J Rheumatol. 32(suppl. 2):1993;27-30.
10. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 94:1998;557-572.
11. Barnes P.J. Molecular mechanisms of corticosteroids in allergic diseases. Allergy. 56:2001;928-936.
12. Batchelor T.T., Taylor L.P., Thaler H.T., Posner J.B., DeAngelis L.M. Steroid myopathy in cancer patients. Neurology. 48:1997;1234-1238.
13. Beato M., Chalepakis G., Schauer M., Slater E.P. DNA regulatory elements of steroid hormones. J Steroid Biochem. 32:1989;737-747.
14. Beer H.D., Longaker M.T., Werner S. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J Invest Dermatol. 109:1997;132-138.
15. Beer H.D., Fässler R., Werner S. Gluocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm. 59:2000;217-239.
16. Bell N.H. The glucocorticoid withdrawal syndrome. Adv Exp Med Biol. 171:1984;293-299.
17. Bell R., Carr A., Thompson P. Managing corticosteroid-induced osteoporosis in medical outpatients. J R Coll Physicians Lond. 31:1997;158-161.
18. Belvisi M.G., Wicks S.L., Battram C.H., Bottoms S.E.W., Redford J.E., Woodman P., Brown T.J., Webber S.E., Foster M.L. Therapeutic benefit of a dissociated glucocorticoid and the relevance of an in vivo separation of transrepression from transactivation activity. J Immunol. 166:2001;1975-1982.
19. Bentson J., Reza M., Winter J., Wilson G. Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr. 2:1978;16-23.
20. Beurton F., Bandyopadhyay U., Dieumegard B., Barouki R., Aggerbeck M. Delineation of insulin-responsive sequence in rat cytosolic aspartate aminotransferase gene: binding sites for hepatocyte nuclear factor-3 and nuclear factor I. Biochem J. 343:1999;687-695.
21. Bielefeld P. Present status of cortisone myopathy. Rev Med Interne. 17:1996;255-261.
22. Biering H., Knappe G., Gerl H., Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca. 27:2000;27-31.
23. Bircan Z., Soran M., Yildirim I., Dogan M., Sahin A., Bilici A., Danaci M. The effect of alternate-day low dose prednisolone on bone age in children with steroid dependent nephrotic syndrome. Int Urol Nephrol. 29:1997;357-361.
24. Black R.L., Oglesby R.B., von Sallmann L., Bunim J.J. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA. 1174:1960;166-171.
25. Blackie J.D., Gibson P., Murree-Allen K., Saul W.P. Acute myopathy in status asthmaticus. Clin Exp Neurol. 30:1993;72-81.
26. Bowyer S.L., LaMothe M.P., Hollister J.R. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 76:1985;234-242.
27. Brauchle M., Fässler R., Werner S. Suppression of keratinocyte growth factor expression by GCs in vitro and during wound healing. J Invest Dermatol. 105:1995;579-584.
28. Brennan F.E., Fuller P.J. Rapid upregulation of sgk gene expression by corticosteroid in vivo. Mol Cell Endocrinol. 166:2000;129-136.
29. Brown E.S. Chemical dependence involving glucocorticoids. Ann Clin Psychiatry. 9:1997;185-187.
30. Brown E.S., Khan D.A., Nejtek V.A. The psychiatric side effects of corticosteroids. Ann Allergy Asthma Immunol. 83:1999;495-504.
31. Carlstedt-Duke J. GC receptor β: view II. Trends Endocrinol Metab. 10:1999;339-342.
32. Carnahan M.C., Goldstein D.A. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 11:2000;478-483.
33. Carpenter W.T. Jr., Gruen P.H. Cortisol's effects on human mental functioning. J Clin Psychopharmacol. 2:1982;91-101.
34. Carson J.L., Strom B.L., Schinnar R., Duff A., Sim E. The low risk of upper gastroinstestinal bleeding in patients dispensed corticosteroids. Am J Med. 91:1991;223-228.
35. Cato A.C., Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays. 18:1996;371-378.
36. Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 142:2000;931-936.
37. Chen S.J., Yuan W., Lo S., Trojanowska M., Varga J. Interaction of Smad3 with a proximal Smad-binding element of the human α2(I) procollagen gene promoter required for transcriptional activation by TGF-β J Cell Physiol. 183:2000;381-392.
38. Chen S.Y., Bhargava A., Mastroberardino L., Meijer O.C., Wang J., Buse P., Firestone G.L., Verrey F., Pearce D. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA. 96:1999;2514-2519.
39. Chiu M.Y., Sprague S.M., Bruce D.S., Woodle E.S., Thistlethwaite J.R. Jr., Josephson M.A. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol. 9:1998;677-683.
40. Cline J.C., Davis S.M. Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Ann Pharmacother. 31:1997;775-776.
41. Coghlan M.J., Kym P.R., Elmore S.W., Wang A.X., Luly J.R., Wilcox D., Stashko M., Lin C.W., Miner J., Tyree C., Nakane M., Jacobson P., Lane B.C. Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity. J Med Chem. 44:2001;2879-2885.
42. Cooper C., Coupland C., Michell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 54:1995;49-52.
43. Covar R.A., Leung D.Y., McCormick D., Steelman J., Zeitler P., Spahn J.D. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol. 106:2000;651-659.
44. Crosson S.M., Roesler W.J. Hormonal regulation of the phosphoenolpyruvate carboxykinase gene. Role of specific CCAAT/enhancer-binding protein isoforms. J Biol Chem. 275:2000;5804-5809.
45. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. GCs repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA. 97:2000;3919-3924.
46. Del Monaco M., Covello S.P., Kennedy S.H., Gilinger G., Litwack G., Uitto J. Identification of novel GC-response elements in human elastin promoter and demonstration of nucleotide sequence specificity of the receptor binding. J Invest Dermatol. 108:1997;938-942.
47. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:1998;3091-3100.
48. Depczynski B., Daly B., Campbell L.V., Chisholm D.J., Keogh A. Predicting the occurence of diabetes mellitus in recipients of heart transplants. Diabetes Med. 17:2000;15-19.
49. Derby L., Maier W.C. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 105:2000;912-916.
50. Di Fazano C.S., Messica O., Quennesson S., Quennesson E.R., Inaoui R., Vergne P., Bonnet C., Bertin P., Treves R. Two new cases of glucocorticoid-induced pancreatitis. Rev Rheum Engl Ed. 66:1999;235.
51. Dittmar K.D., Pratt W.B. Folding of the GC receptor by reconstituted hsp90-based chaperone machinery. The initial hsp90.p60.hsp70-dependent step is sufficient for creating the steroid binding conformation. J Biol Chem. 272:1997;13047-13054.
52. Dixon R.B., Christy N.P. On the various forms of corticosteroid withdrawal syndrome. Am J Med. 68:1980;224-230.
53. Dowell S.F., Bresee J.S. Severe varicella associated with steroid use. Pediatrics. 92:1993;223-228.
54. Drouin J., Sun Y.L., Chamberland M., Gauthier Y., De L.A., Nemer M., Schmidt T.J. Novel GC receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J. 12:1993;145-156.
55. Eaton D.C., Becchetti A., Ma H., Ling B.N. Renal sodium channels: regulation and single channel properties. Kidney Int. 48:1995;941-949.
56. Ehrlich H.P., Hunt T.K. Effects of cortisone and vitamin A on wound healing. Ann Surg. 167:1968;324-328.
57. Ekblom M., Fässler R., Tomasini-Johannson B., Nilsson K., Ekblom P. Downregulation of tenascin expression by GCs in bone marrow stromal cells and in fibroblasts. J Cell Biol. 123:1993;1037-1045.
58. Escoubet B., Coureau C., Bonvalet J.P., Farman N. Noncoordinate regulation of epithelial Na channel and Na pump subunit mRNAs in kidney and colon by aldosterone. Am J Physiol. 272:1997;C1482-C1491.
59. Ettinger B., Chidambaran P., Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care. 7:2001;597-605.
60. Everson G.T., Trouillot T., Wachs M., Bak T., Steinberg T., Kam I., Shrestha R., Stegall M. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg. 5(4 suppl. 1):1999;S48-S57.
61. Falduto M.T., Hickson R.C., Young A.P. Antagonism by glucocorticoids and exercise on expression of glutamine synthetase in skeletal muscle. FASEB J. 3:1989;2623-2628.
62. Fässler R., Sasaki T., Timpl R., Chu M.L., Werner S. Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and GC-treated mice. Exp Cell Res. 222:1996;111-116.
63. Felner E.I., Thompson M.T., Ratliff A.F., White P.C., Dickson B.A. Time course of recovery of adrenal function in children treated for leukemia. J Pediatr. 137:2000;21-24.
64. Fernandez-Miranda C., de la Calle A., Morales J.M., Guijarro C., Aranda J.L., Gomez-Sanz R., Gomez-Izquierdo T., Larumbe S., Moreno E., Rodicio J.L., del Palacio A. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study. Clin Transplant. 12:1998;136-141.
65. Fisher J.E., Smith R.S., Lagrandeur R., Loren R.P. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol. 90:1997;880-883.
66. Frank S., Madlener M., Werner S. Transforming growth factors β1, β2 and β3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem. 271:1996;10188-10193.
67. Frank S., Madlener M., Pfeilschifter J., Werner S. Induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin-cofactor-synthesizing enzyme GTP-cyclohydrolase I during cutaneous repair. J Invest Dermatol. 262:1998;16300-16304.
68. Fricchione G., Ayyala M., Holmes V.F. Steroid withdrawal psychiatric syndromes. Ann Clin Psychiatry. 1:1989;99-108.
69. Friedman J.E., Sun Y., Ishizuka T., Farrell C.J., McCormack S.E., Herron L.M., Hakimi P., Lechner P., Yun J.S. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hypoglycemia are regulated by GCs in genetically obese db/db transgenic mice. J Biol Chem. 272:1997;31475-31481.
70. Garbe E., LeLorier J., Boivin J.F., Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 350:1997;979-982.
71. Garbe E., LeLorier J., Boivin J.F., Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 277:1997;722-727.
72. Garbe E., Suissa S., LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA. 280:1998;539-543.
73. Giguere V., Hollenberg S.M., Rosenfeld M.G., Evans R.M. Functional domains of the human GC receptor. Cell. 46:1986;645-652.
74. Glowniak J.V., Loriaux D.L. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery. 121:1997;123-129.
75. Goichot B., Wicky C., Grunenberger F., Schlienger J.L. Hypothalamo-pituitary-adrenocortical function during and after steroid therapy: recent data and critical review. Ann Endocrinol (Paris). 61:2000;452-458.
76. Goldberg R.L., Wise T.N. Corticosteroid abuse revisited. Int J Psychiatry Med. 16:1986-1987;145-149.
77. Goldstein M.F., Fallon J.J. Jr., Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest. 116:1999;1733-1749.
78. Gonzalez-Quintela A., De la Mata M., Varo E., Fraga E., Montero J.L., Lopez-Cillero P., Mino G., Pera C. Incidence of new onset diabetes mellitus in liver transplant recipients immunopressed with deflazacort. TANSE. 6:1995;107-115.
79. Goodwin J.S. Antiinflammatory drugs. Stites D.P., Terr A.I., Parslow T.G. Basic and Clinical Immunology. 8th edn. 1994;786-795 Appleton and Lange, East Norwalk.
80. Gould E., Tanapat P., McEwen B.S., Flugge G., Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA. 95:1998;3168-3171.
81. Grange T., Roux J., Rigaud G., Pictet R. Cell-type specific activity of two GC responsive units of rat tyrosine aminotransferase gene is associated with multiple binding sites for C/EBP and a novel liver-specific nuclear factor. Nucleic Acids Res. 19:1991;131-139.
82. Granner D.K., Hargrove J.L. Regulation of the synthesis of tyrosine aminotransferase: the relationship to mRNATAT. Mol Cell Biochem. 53-54:1983;113-128.
83. Gras M.P., Verrecchia F., Uitto J., Mauviel A. Downregulation of human type VII collagen (COL7A1) promoter activity by dexamethasone. Exp Dermatol. 10:2001;28-34.
84. Gupta D., Behera D., Lalrinmawia H., Dash R.J. Hypothalamo-pituitary-adrenal axis function in asthmatics taking low dose inhaled beclomethasone dipropionate. J Assoc Physicians India. 48:2000;682-684.
85. Hall R.C., Popkin M.K., Stickney S.K., Gardner E.R. Presentation of the steroid psychosis. J Nerv Ment Dis. 167:1979;229-236.
86. Hargrove J.L., Granner D.K. Biosynthesis and intracellular processing of tyrosine aminotransferase. Christen P., Metzler D.E. Transaminases. 1985;511-532 John Wiley and Sons, New York.
87. Hasegawa T., Ishihara K., Fujii H., Hajiro T., Watanabe I., Nishimura T., Okazaki M., Katakami N., Umeda B. Influence of high dose inhaled steroids on hypothalamo-pituitary-adrenal axis function in Japanese patients with asthma: a comparison over the course of time. Intern Med. 35:1996;362-366.
88. Haskett R.F. Diagnostic characterization of psychiatric disability in Cushing's syndrome. Am J Psychiatry. 142:1985;911-916.
89. Henriksen J.E., Alford F., Ward G.M., Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia. 40:1997;1439-1448.
90. Henzen C., Suter A., Lerch E., Urbinelli R., Schorno X.H., Briner V.A. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 355:2000;542-545.
91. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., Thompson E.B., Rosenfeld M.G., Evans R.M. Primary structure and expression of a functional human GC receptor cDNA. Nature. 318:1985;635-641.
92. Hoyer D., Martin G.R. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res. 73:1996;263-268.
93. Hübner G., Brauchle M., Smola H., Madlener M., Fässler R., Werner S. Differential regulation of pro-inflammatory cytokines during wound healing in normal and GC-treated mice. Cytokine. 8:1996;548-556.
94. Hummel M., Warnecke H., Schuler S., Luding K., Hetzer R. Risiko der Nebennierenrindeninsuffizienz nach Herztransplantation. Klin Wochenschr. 69:1991;269-273.
95. Ihle R., Stobbe H., Heinrich H.G. Therapeutische Grundlagen. Schulz F.H., Stobbe H. Grundlagen und Klinik innerer Erkrankungen. 1989;42-81 Volk und Gesundheit, Berlin.
96. Jantzen H.M., Strähle U., Gloss B., Stewart F., Schmid W., Boshart M., Miksicek R., Schütz G. Cooperativity of GC response elements located far upstream of the tyrosine aminotransferase gene. Cell. 49:1987;29-38.
97. Julius D. Molecular biology of serotonin receptors. Annu Rev Neurosci. 14:1991;335-360.
98. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell. 93:1998;487-490.
99. Kassel O., Sancono A., Krätzschmar J., Kreft B., Stassen M., Cato A.C. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20:2001;7108-7116.
100. Katz H.I., Prawer S.E., Mooney J.J., Samson C.R. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol. 20:1989;731-735.
101. Kauh Y.C., Rouda S., Mondragon G., Tokarek R., diLeonardo M., Tuan R.S., Tan E.M. Major suppression of pro-alpha1(I) type I collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamcinolone acetonide. J Am Acad Dermatol. 37:1997;586-589.
102. Kellendonk C., Tronche F., Reichardt H.M., Schutz G. Mutagenesis of the glucocorticoid receptor in mice. J Steroid Biochem Mol Biol. 69:1999;253-259.
103. Kelly J.J., Mangos G., Williamson P.M., Whitworth J.A. Cortisol and hypertension. Clin Exp Pharmacol Physiol. 25(suppl.):1998;S51-S56.
104. Kennedy W.A., Laurier C., Gautrin D., Ghezzo H., Pare M., Malo J.L., Contandriopopoulos A.P. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epidemiol. 53:2000;696-701.
105. Kloehn S., Arendt T., Reinecke-Luthge A., Klomp H.J., Monig H. Cushing syndrome with life-threatening infectious complications. Dtsch Med Wochenschr. 122:1997;1547-1552.
106. Kojima M., Shui Y.B., Sasaki K. Topographic distribution of prednisolone in the lens after organ culture. Ophthalmic Res. 27(suppl. 1):1995;25-33.
107. Kolbe L., Kligman A.M., Schreiner V., Stoudenmayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 7:2001;73-77.
108. Kountz D.S., Clark C.L. Safely withdrawing patients from chronic glucocorticoid therapy. Am Fam Physician. 55:1997;521-525.
109. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., Roberson P.K., Weinstein R.S., Jilka R.L., Manolagas S.C. Nongeotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 104:2001;719-730.
110. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
111. Lane N.E., Lukert B. The science and therapy of GC-induced bone loss. Endocrinol Metab Clin North Am. 27:1998;465-483.
112. LaPier T.K. GC-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehabil. 17:1997;76-84.
113. Lawrence M.S., Sapolsky R.M. Glucocorticoids accelerate ATP loss following metabolic insults in cultured hippocampal neurons. Brain Res. 646:1994;303-306.
114. Leibovich S.J., Ross R. The role of macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol. 78:1975;71-100.
115. Leung D.Y., Hamid Q., Vottero A., Szefler S., Surs W., Minshall E., Chrousos G.P., Klemm D.J. Association of GC insensitivity with increased expression of GC receptor β J Exp Med. 186:1997;1567-1574.
116. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell. 104:2001;545-556.
117. 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry. 43:1998;547-573.
118. Lubach D., Rath J., Kietzmann M. Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. Dermatology. 190:1995;51-55.
119. Lutjen-Drecoll E., May C.A., Polansky J.R., Johnson D.H., Bloemendal H., Nguyen T.D. Localization of the stress proteins alpha B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. Invest Ophthalmol Vis Sci. 39:1998;517-525.
120. Määttä A., Penttinen R.P. A fibroblast protein binds the 3′-untranslated region of pro-alpha 1(I) collagen mRNA. Biochem J. 295:1993;691-698.
121. Madlener M., Parks W.C., Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair in mice. Exp Cell Res. 242:1998;201-210.
122. Magarinos A.M., Verdugo J.M., McEwen B.S. Chronic stress alters synaptic terminal structure in hippocampus. Proc Natl Acad Sci USA. 94:1997;14002-14008.
123. Mahonen A., Jukkola A., Risteli L., Risteli J., Maenpaa P.H. Type I procollagen synthesis is regulated by steroids and related hormones in human osteosarcoma cells. J Cell Biochem. 68:1998;151-163.
124. Maibach, H.I., & Surber, C. (1992). Topical Corticosteroids. Basel, München, Paris, London, New York, New Dehli, Bangkok, Singapore, Tokyo and Sydney: Karger.
125. Manabe S., Bucala R., Cerami A. Nonenzymatic addition of GCs to lens proteins in steroid-induced cataracts. J Clin Invest. 74:1984;1803-1810.
126. Manolagas S.C., Weinstein R.S. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 14:1999;1061-1066.
127. McEvoy C.E., Ensrud K.E., Bender E., Genant H.K., Yu W., Griffith J.M., Niewoehner D.E. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 157:1998;704-709.
128. Meyer T., Carlstedt-Duke J., Starr D.B. A weak TATA box is a prerequisite for gluocorticoid-dependent repression of the osteocalcin gene. J Biol Chem. 272:1997;30709-30714.
129. Mitchell P., Cumming R.G., Mackey D.A. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology. 106:1999;2301-2306.
130. Mygind N., Dahl R. The rationale for use of topical corticosteroids in allergic rhinitis. Clin Exp Allergy. 26(suppl. 3):1996;2-10.
131. Nashel D.J. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med. 80:1986;925-929.
132. Nies, C. (1993). http://www.nebenniere.de/cushing.JPG; http://www.nebenniere.de/infopatient-erkrankungen.htm.
133. Oakly R.H., Sar M., Cidlowsky J.A. The human GC receptor β isoform. Expression, biochemical properties, and putative function. J Biol Chem. 271:1996;9550-9559.
134. O'Brien R.M., Noisin E.L., Suwanichkul A., Yamasaki T., Lucas P.C., Wang J.C., Powell D.R., Granner D.K. Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 genes. Mol Cell Biol. 15:1995;1747-1758.
135. Oikarinen A., Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol. 16:1991;416-419.
136. Oikarinen A., Autio P., Kiistala U., Risteli L., Risteli J. A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical GC treatment. J Invest Dermatol. 98:1992;220-225.
137. Oikarinen A., Haapasaari K.M., Sutinen M., Tasanen K. The molecular basis of GC-induced skin atrophy: topical GC apparently decreases both collagen synthesis and corresponding collagen mRNA level in human skin in vivo. Br J Dermatol. 139:1998;1106-1110.
138. Onwubalili J.K., Obineche E.N. High incidence of post-transplant diabetes mellitus in a single-centre study. Nephrol Dial Transplant. 7:1992;346-349.
139. Ortonne J.P. Skin atrophogenic potential of methylprednisolone aceponate (MPA). J Eur Acad Dermatol Venereol. 3:1994;S13-S18l.
140. Otto C., Reichardt H.M., Schütz G. Absence of GC receptor-β in mice. J Biol Chem. 272:1997;26665-26668.
141. Pearce G., Ryan P.F., Delmas P.D., Tabensky D.A., Seeman E. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol. 37:1998;292-299.
142. Pérez P., Page A., Brano A., Del Rio M., Giménez-Conti I., Budunova I., Slaga T.J., Jorcano J.L. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J. 15:2001;2030-2032.
143. Piper J.M., Ray W.A., Daugherty J.R., Griffin M.R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 114:1991;735-740.
144. Price S.R., Du J.D., Bailey J.L., Mitch W.E. Molecular mechanisms regulating protein turnover in muscle. Am J Kidney Dis. 37(1 suppl. 2):2001;S112-S114.
145. Raghow R., Gossage D., Kang A.H. Pretranslational regulation of type I collagen, fibronectin, and a 50-kilodalton noncollagenous extracellular protein by dexamethasone in rat fibroblasts. J Biol Chem. 261:1986;4677-4684.
146. Raul Ariza-Andraca C., Barile-Fabris L.A., Frati-Munari A.C., Baltazar-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res. 29:1998;259-262.
147. Reed B.R., Clark R.A. Cutaneous tissue repair: practical implications of current knowledge II. Am Acad Dermatol. 13:1985;919-941.
148. Reichardt H.M., Schütz G. GC signalling - multiple variations of a common theme. Mol Cell Endocrinol. 146:1998;1-6.
149. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 93:1998;531-541.
150. Reichardt H.M., Tronche F., Berger S., Kellendonk C., Schütz G. New insights into GC and mineralocorticoid signaling: lessons from gene targeting. Adv Pharmacol. 47:2000;1-21.
151. Reichardt H.M., Tuckermann J.P., Göttlicher M., Vujic M., Weih F., Angel P., Herrlich P., Schütz G. Repression of inflammatory responses in the absence of DNA-binding by the glucocorticoid receptor. EMBO J. 20:2001;7168-7173.
152. Reid I.R. Glucocorticoid-induced osteoporosis. Baillieres Clin Endocrinol Metab. 14:2000;279-298.
153. Rendina E.A., Venuta F., Ricci C. Effects of low-dose steroids on bronchial healing after sleeve resection. A clinical study. J Thorac Cardiovasc Surg. 104:1992;888-891.
154. Richardson C.T. Pathogenetic factors in peptic ulcer disease. Am J Med. 79:1985;1-7.
155. Rigaud G., Roux J., Pictet R., Grange T. In vivo footprinting of rat TAT gene: dynamic interplay between the GC receptor and a liver-specific factor. Cell. 67:1991;977-986.
156. Robertson D.B., Maibach H.I. Topical corticosteroids. Int J Dermatol. 21:1982;59-67.
157. Robinzon B., Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology. 38:1999;488-495.
158. Rodriguez L.A.G., Hernández-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 3:2001;98-101.
159. Roux J., Pictet R., Grange T. Hepatocyte nuclear factor 3 determines the amplitude of the GC response of the rat tyrosine aminotransferase gene. DNA Cell Biol. 14:1995;385-396.
160. Ruppert S., Boshart M., Bosch F.X., Schmid W., Fournier R.E., Schütz G. Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes. Cell. 61:1990;895-904.
161. Russell S.B., Trupin J.S., Kennedy R.Z., Russell J.D., Davidson J.M. GC regulation of elastin synthesis in human fibroblasts: down-regulation in fibroblasts from normal dermis but not from keloids. J Invest Dermatol. 104:1995;241-245.
162. Sandberg N. Time relationship between administration of cortisone and wound healing in rats. Acta Chir Scand. 127:1964;446-450.
163. Sanders B.P., Portman R.J., Ramey R.A., Hill M., Strunk R.C. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol. 89:1992;816-821.
164. Sapolsky R.M., Packan D.R., Vale W.W. Glucocorticoid toxicity in the hippocampus: in vitro demonstration. Brain Res. 453:1988;367-371.
165. Sapolsky R.M., Uno H., Rebert C.S., Finch C.E. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 10:1990;2897-2902.
166. Sarnstrand B., Brattsand R., Malmstrom A. Effect of GCs on glycosaminoglycan metabolism in cultured human skin fibroblasts. J Invest Dermatol. 79:1982;412-417.
167. Sartori T.M., Maurizio P.G., Sara P., Ugolino L., Annalisa A., Panagiotis T., Massimo F., Anonio G. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant. 18:1999;693-700.
168. Sassi H., Pictet R., Grange T. GCs are insufficient for neonatal gene induction in the liver. Proc Natl Acad Sci USA. 95:1998;5621-5625.
169. Satel S.L. Mental status changes in children receiving glucocorticoids. Review of the literature. Clin Pediatr. 29:1990;383-388.
170. Sato A., Funder J.W., Okubo M., Kubota E., Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 8:1995;823-828.
171. Sayegh R., Auerbach S.D., Li X., Loftus R.W., Husted R.F., Stokes J.B., Thomas C.P. GC induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5′-flanking region of the human epithelial sodium channel α subunit gene. J Biol Chem. 274:1999;12431-12437.
172. Schneikert J., Hübner S., Martin E., Cato A.C. A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of GC receptor activity. J Cell Biol. 146:1999;929-940.
173. Schüle R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., Verma I.M., Evans R.M. Functional antagonism between oncoprotein c-Jun and the GC receptor. Cell. 62:1990;1217-1226.
174. Schulze S., Andersen J., Overgaard H., Norgard P., Nielsen H.J., Aasen A., Gottrup F., Kehlet H. Effect of prednisolone on the systemic response and wound healing after colonic surgery. Arch Surg. 132:1997;129-135.
175. Schwabe U. Corticosteroide. Schwabe P. Arzneiverordnungs-Report 1996. 1996;184-188 Fischer, Stuttgart.
176. Schweizer-Groyer G., Cadepond F., Jibard N., Neau E., Segard-Maurel I., Baulieu E.E., Groyer A. Stimulation of transcription in vitro from a liver-specific promoter by human glucocorticoid receptor (hGRalpha). Biochem J. 324:1997;823-831.
177. Sclafani A.P., Gordon L., Chadha M., Romo T. 3rd Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Dermatol Surg. 22:1996;569-574.
178. Scott D.K., Strömstedt P.E., Wang J.C., Granner D.K. Further characterization of the GC response unit in the phosphoenolpyruvate carboxykinase gene. The role of the GC receptor-binding sites. Mol Endocrinol. 12:1998;482-491.
179. Senderovitz T., Viskum K. Corticosteroid and tuberculosis. Respir Med. 88:1994;561-565.
180. Shee C.D. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med. 84:1990;229-233.
181. Sholter D.E., Armstrong P.W. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 16:2000;505-511.
182. Silvestrini G., Ballanti P., Patacchioli F.R., Mocetti P., Di Grezia R., Wedard B., Angelucci L., Bonucci E. Evaluation of apoptosis and the GC receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone. 26:2000;33-42.
183. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319.
184. Simons F.E.R., Persaud M.P., Gillespie C.A., Cheang M., Shuckett E.P. Absence of posterior subcapsular cataracts in young patients treated with glucocorticoids. Lancet. 342:1993;776-778.
185. Skoner D.P., Rachelefsky G.S., Meltzer E.O., Chervinsky P., Morris R.M., Seltzer J.M., Storms W.W., Wood R.A. Detection of growth supression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 105:2000;E23.
186. Song C.Z., Tian X., Gelehrter T.D. GC receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci USA. 96:1999;11776-11781.
187. Stanbury R.M., Graham E.M. Systemic corticosteroid therapy-side effect and their management. Br J Ophthamol. 82:1998;704-708.
188. Stein-Behrens B.A., Lin W.J., Sapolsky R.M. Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus. J Neurochem. 63:1994;596-602.
189. Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H., Edwards C.R. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 2:1987;821-824.
190. Stokes J.B., Sigmund R.D. Regulation of rENaC mRNA by dietary NaCl and steroids: organ, tissue, and steroid heterogeneity. Am J Physiol. 274:1998;C1699-C1707.
191. Strickland I., Kisich K., Hauk P.J., Vottero A., Chrousos G.P., Klemm D.J., Leung D.Y.M. High constitutive glucocorticoid receptor β in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med. 193:2001;585-593.
192. Stromstedt P.E., Poellinger L., Gustafsson J.A., Carlstedt D.J. The GC receptor binds to the TATA box of human osteocalcin promoter: a potential mechanism of negative regulation. Mol Cell Biol. 11:1991;3379-3383.
193. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis. 11:1989;954-963.
194. Sugar A., Bokosky J.E., Meyer R.F. A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. Cornea. 3:1984-1985;268-271.
195. Töx U., Goeser T., Steffen H.M. Ulkusprophylaxe bei Dauertherapie mit Glukokortikoiden? Dtsch Med Wochenschr. 126:2001;766-768.
196. Tripathi R.C., Parapuram S.K., Tripathi B.J., Zhong Y., Chalam K.V. Corticosteroids and glaucoma risk. Drugs Aging. 15:1999;439-450.
197. Tuckermann J.P., Reichardt H.M., Arribas R., Richter K.H., Schutz G., Angel P. The DNA binding-independent function of the GC receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol. 147:1999;1365-1370.
198. Ulman I., Mutaf O. A critique of systemic steroids in the management of caustic esophageal burns in children. Eur J Pediatr Surg. 8:1998;71-74.
199. Uno H., Lohmiller L., Thieme C., Kemnitz J.W., Engle M.J., Roecker E.B., Farrell P.M. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res. 53:1990;157-167.
200. Venkatesh V.C., Katzberg H.D. GC regulation of epithelial sodium channel genes in human fetal lung. Am J Physiol. 273:1997;L227-L233.
201. Virgin C.E. Jr., Ha T.P., Packan D.R., Tombaugh G.C., Yang S.H., Horner H.C., Sapolsky R.M. Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. J Neurochem. 57:1991;1422-1428.
202. Vottero A., Chrousos G.P. GC receptor β: view I. Trends Endocrinol Metab. 10:1999;333-338.
203. Vuorio E., Crombrugghe B. The family of collagen genes. Annu Rev Biochem. 59:1990;837-872.
204. Wahl S.M. GCs and wound healing. Schleimer R.P., Claman H.N., Oronsky A.L. Anti-inflammatory steroid action. Basic and clinical aspects. 1989;280-302 Academic Press, San Diego.
205. Wajngot A., Giacca A., Grill V., Vranic M., Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci USA. 89:1992;6035-6039.
206. Walfisch A., Hallak M., Mazor M. Multiple courses of antenatal steroids: risks and benefits. Obstet Gynecol. 98:2001;491-497.
207. Walsh L.J., Wong C.A., Pringle M., Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Br Med J. 313:1996;344-346.
208. Watanabe Y., Gould E., Daniels D.C., Cameron H., McEwen B.S. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol. 222:1992;157-162.
209. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by GCs. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 102:1998;274-282.
210. Winkelstein A. Immunosuppressive therapy. Stites D.P., Terr A.T., Parslow T.G. Basic and Clinical Immunology. 8th edn. 1994;767-780 Appleton and Lange, San Mateo.
211. Wissink S., Meijer O., Pearce D., van Der Burg B., van Der Saag P.T. Regulation of the rat serotonin-1A receptor gene by corticosteroids. J Biol Chem. 275:2000;1321-1326.
212. Wolfe F., Hawley D.J. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol. 27:2000;1668-1673.
213. Wolkowitz O.M., Reus V.I., Canick J., Levin B., Lupien S. Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann N Y Acad Sci. 823:1997;81-96.
214. Wolthers O.D. Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids. Eur Respir J. 9:1996;821-827.
215. Wolthers O.D., Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. Br Med J. 301:1990;145-148.
216. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1998;1329-1337.
217. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S.I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.
218. Yoshiuchi I., Shingu R., Nakajima H., Hamaguchi T., Horikawa Y., Yamasaki T., Oue T., Ono A., Miyagawa J.I., Namba M., Hanfusa T., Matsuzawa Y. Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients. J Clin Metab. 83:1998;1016-1019.
219. Zanardi V.A., Magna L.A., Costallat L.T. Cerebral atrophy related to corticotherapy in systemic lupus erythematosus (SLE). Clin Rheumatol. 20:2001;245-250.
220. Zhou L., Li Y., You B.Y. Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to glaucoma. Int J Mol Med. 2:1998;339-346.
221. Zhou Z., Vollrath D. A cellular assay distinguishes normal and mutant TIGR/myocilin protein. Hum Mol Genet. 8:1999;2221-2228.
222. Ziegler R., Kasperk C. Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids. 63:1998;344-348.
223. Zimmerman C.C., Lingappa V.R., Richards J.E., Rozsa F.W., Lichter P.R., Polansky J.R. A trabecular meshwork GC response (TIGR) gene mutation affects translocational processing. Mol Vis. 5:1999;19-24.